Celebrating his company’s upsized initial public offering (IPO), Septerna CEO Jeffrey Finer ... On the same day last month, Bicara Therapeutics, MBX Bioscences and Zenas BioPharma went public ...

Shares of Septerna SEPN surged 51% on May 14 after ... Several other companies like Amgen AMGN and Viking Therapeutics are also making rapid progress in the development of GLP-1-based candidates ...

The deal is valued at up to $2.2bn, including more than $200m in upfront and near-term payments to Septerna. The partnership centres on the discovery and development of oral therapeutics aimed at ...

You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk said Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to ...

The deal is big for a Bay Area drug industry in need of big wins. Septerna shares surged 55% in early trading. Peninsula startup nets Nobel winner, $100M to change drug discovery How taming a ...